Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD5672 · 5 trials · 2 indications
The number of participants with greater to or equal to 20% improvement in the ACR composite score (a measure of RA symptoms including: joint swelling and tenderness; patient's assessment of pain, disease activity and physical function; physician's assessment of disease activity; and CRP) after 12 Weeks' treatment.
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | - |
| 2 | EXPERIMENTAL | 20mg |
| 3 | EXPERIMENTAL | 50mg |
| 4 | EXPERIMENTAL | 100mg |
| 5 | EXPERIMENTAL | 150mg |
| 6 | PLACEBO_COMPARATOR | - |
| A | EXPERIMENTAL | 600mg AZD5672 + Moxifloxacin placebo |
| B | EXPERIMENTAL | 100mg AZD5672 + Moxifloxacin placebo |
| C | ACTIVE_COMPARATOR | AZD5672 placebo + Moxifloxacin 400mg |
| D | PLACEBO_COMPARATOR | AZD5672 placebo + Moxifloxacin placebo |
| Name | Type | Description |
|---|---|---|
| AZD5672 | DRUG | 20 mg oral, once daily |
| Etanercept | DRUG | 50 mg, subcutaneous injection, weekly |
| Placebo | DRUG | placebo, oral, once daily |
| Moxifloxacin | DRUG | 1 x 400mg capsule, oral, single dose |
Inclusion Criteria: * Diagnosis of RA with active disease defined as: ≥4 swollen joints and ≥6 tender/painful joints, and either have (blood tests) elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). * At least one of the following: documented history of positive rheumatoid f...
Top 20 of 31 competitors
AZD5672 is an investigational small molecule developed by AstraZeneca PLC (ticker AZN). It has been studied in Phase 1 and Phase 2 clinical trials for rheumatoid arthritis and renal impairment. It is a CCR5 antagonist. The drug is not approved and remains in clinical development.
AZD5672 has been studied as a potential treatment for rheumatoid arthritis. A Phase 2 proof of concept and dose ranging study (NCT00713544) enrolled 373 patients with rheumatoid arthritis across multiple countries. Phase 1 trials also included rheumatoid arthritis as a condition. The drug is investigational and not approved for any use.
AZD5672 targets CCR5, a chemokine receptor. It acts as a CCR5 antagonist. By blocking CCR5, the drug may interfere with inflammatory signaling pathways relevant to rheumatoid arthritis. This mechanism is under investigation in clinical trials.
AZD5672 is being developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca sponsored the clinical trials for this drug, including Phase 1 and Phase 2 studies in rheumatoid arthritis and renal impairment.
AZD5672 has completed Phase 1 and Phase 2 clinical trials. The most advanced trial was a Phase 2 proof of concept and dose ranging study in rheumatoid arthritis (NCT00713544). The drug is investigational and has not been approved by the FDA or any regulatory agency.
AZD5672 has been evaluated in four completed clinical trials. These include NCT00887770, a Phase 1 cardiac conduction study; NCT00871767, a Phase 1 bioavailability study; NCT00715702, a Phase 1 safety study in renally impaired subjects; and NCT00713544, a Phase 2 proof of concept and dose ranging study in rheumatoid arthritis.